Search Results
49 results found-
When integrated with workflows within the laboratory environment to increase laboratory facilities, this advanced technology uses an accuracy, enhance result reproducibility and improve augmented reality headset and a linked tablet, to offer efficiency by decoupling productivity from scientists.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
providing information that is misleading AFSTYLA®, a novel recombinant factor VIII product for the due to the fact it is premature or preliminary in nature, relates treatment of haemophilia A patients, also delivered strong to commercially sensitive contracts, would undermine the growth despite intense competition in this market.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
Today, CSL - including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor - provides lifesaving products to patients in more than 100 countries and employs 30,000 people.
https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE -
Key findings include that vaccination averts between 180,000 and 626,000 cases of influenza per year in England, and that flu vaccination helps avert between 5,678 and 8,800 premature deaths per year.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
CSL's Speak Up hotline can be accessed by toll-free numbers or online and is promoted periodically through employee communications and trainings.
https://www.csl.com/-/media/csl/documents/csl-statement-on-modern-slavery-2023.pdf -
We will continue to engage with suppliers to develop our understanding and verify the locations where suppliers are manufacturing or sourcing the products that we buy.
https://www.csl.com/-/media/csl/documents/csl-statement-on-modern-slavery-2021.pdf -
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of...
https://newsroom.csl.com/csl-vifor -
ST. GALLEN, SWITZERLAND, March 28, 2024 / PRNewswire / -- CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
https://newsroom.csl.com/2024-03-28-Vafseo-R-approved-by-the-U-S-FDA-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients -
Adverse events (AEs) leading to premature study discontinuation. •
https://www.csl.com/-/media/shared/documents/clin-trials/csl830_3002_synopsis_15mar2018_public.pdf -
link, to access the online Impact RAP Impact Measurement Questionnaire.
https://www.csl.com/-/media/shared/documents/reconciliation-action-plan/csl-reflect-reconciliation-action-plan-rap-2023.pdf